Anti-IL-17 agents for psoriasis: A review of phase III data

Journal of Drugs in Dermatology

Volumn 15, Issue 3, 2016, Pages 311-316

  Farahnik, Benjamin ^a   Beroukhim, Kourosh ^b   Nakamura, Mio ^c   Abrouk, Michael ^d   Zhu, Tian Hao ^e   Singh, Rasnik ^b   Lee, Kristina ^c   Bhutani, Tina ^c   Koo, John ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; IXEKIZUMAB; SECUKINUMAB; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ARTHRALGIA; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; INJECTION SITE REACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INTERLEUKIN-17; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84975882393     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Rachakonda T, Schupp C, Armstrong A. Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology. 2014;70(3). doi:10.1016/j.jaad.2013.11.013.
2. Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol. 2013;44(2):173–82. doi:10.1007/s12016-012-8306-2.
3. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–93. doi:10.1007/s12016-012-8307-1.
4. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–87. doi:10.1084/jem.20060244.
5. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112–24. doi:10.1111/j.1365-2567.2011.03522.x.
6. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999;162(4):2347–52. Available at: http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid9973514.
7. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7. doi:10.1182/blood-2002-05-1461.
8. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304(6):465–9. doi:10.1007/s00403-012-1229-1.
9. Brown G, Malakouti M, Wang E, Koo J, Levin E. Anti-IL-17 phase II data for psoriasis: A review. J Dermatolog Treat. 2014;26(1):32–6. doi:10.3109/09546634.2013.878448.
10. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81.e1–30. doi:10.1016/j.jaad.2013.12.018.
11. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8).
12. Novartis Pharmaceuticals. Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 [cited 2015 April 3]. Available from: https://clinicaltrials. gov/ct2/show/NCT01874340 NLM Identifier: NCT01874340.
13. Novartis Pharmaceuticals. Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 [cited 2015 April 3]. Available from: https://clinicaltrials. gov/ct2/show/NCT01892436 NLM Identifier: NCT01892436.
14. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87. doi:10.1016/j.ophtha.2012.09.040.
15. Langley R, Elewski B, Lebwohl M, et al. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. N Engl J Med. 2014;371(4):326–38. doi:10.1056/NEJMoa1314258.
16. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–93. doi:10.1111/bjd.13348.
17. Paul, Lacour J -P., Tedremets, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6). doi:10.1111/jdv.12751.
18. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9. doi:10.1016/j.jaad.2015.05.013.
19. AMGEN. News &Events. Amgen to Terminate Participation in Co-development and Commercialization of Brodalumab. Amgen Press Release. Amgen, 22 May 2015. Web. 25 Oct. 2015.
20. Papp K, Reich K, Leonardi C, et al. Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo Controlled Study Through Week 12. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 March 20-24; San Francisco, CA.
21. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14). doi:10.1056/NEJMoa1503824.
22. MacGregor S. Lilly’s Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies. Indianapolis; 21AD:1.
23. Gordon K, et al. Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Double-Blind Phase 3 Induction and Randomized Withdrawal Study (UNCOVER-1). Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 March 20-24; San Francisco, CA.
24. Griffiths C, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993). doi:10.1016/S0140-6736(15)60125-8.
25. Revicki DA, Willian MK, Menter A, Saurat J-HH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (Basel). 2008;216(3):260–70. doi:10.1159/000113150.
26. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–8. doi:10.1126/science.1200439.
27. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015;373(14):1329–39. doi:10.1056/NEJMoa1412679.
28. Wu JJ, Poon K-YTY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50. doi:10.1001/archdermatol.2012.2502.
29. De Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508. doi:10.1002/path.2667.
30. Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses. 2004;63(4):696–8. doi:10.1016/j.mehy.2004.03.009.
31. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17(8):699–706. doi:10.1097/01.mca.0000236288.94553.b4.